search
Back to results

Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER)

Primary Purpose

Septic Shock, Severe Sepsis

Status
Completed
Phase
Not Applicable
Locations
Thailand
Study Type
Interventional
Intervention
Early norepinephrine
Placebo
Sponsored by
Mahidol University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring Septic shock, Severe sepsis, Norepinephrine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > or = 18 years old
  • Diagnosed severe sepsis or septic shock according to survival sepsis campaign 2013
  • Mean arterial pressure < 65 mmHg

Exclusion Criteria:

  • Pregnancy
  • Severe underlying condition that unexpected to survive more than 48 hours
  • Severe peripheral vascular disease
  • Patient who required major surgery within 24 hours

Sites / Locations

  • Siriraj Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Early norepinephrine

Placebo

Arm Description

Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.

5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.

Outcomes

Primary Outcome Measures

Therapeutic goal achievement
Therapeutic goal including Mean arterial blood pressure > or = 65 mmHg Evidence of adequate tissue perfusion which include continuation of urine output > or = 0.5 ml/kg/hour for 2 hours or decreasing of serum lactate > or = 10 percent in 1 to 2 hours.

Secondary Outcome Measures

Mortality rate

Full Information

First Posted
September 16, 2013
Last Updated
January 8, 2018
Sponsor
Mahidol University
Collaborators
Siriraj Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01945983
Brief Title
Early Use of Norepinephrine in Septic Shock Resuscitation
Acronym
CENSER
Official Title
The Comparison Between Early Norepinephrine Use and Standard Treatment During Severe Sepsis and Septic Shock Resuscitation.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
October 3, 2013 (Actual)
Primary Completion Date
August 2017 (Actual)
Study Completion Date
August 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mahidol University
Collaborators
Siriraj Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Current septic shock guideline recommends fluid resuscitation as the first treatment. Vasopressors, including norepinephrine is recommended to start after achieve adequate fluid therapy. This can cause a certain duration of systemic hypotension before vasopressor is commenced. Initiation of norepinephrine together with fluid therapy soon after diagnosis of septic shock may increase blood pressure quicker than start treatment with intravenous fluid alone. The rapid restoration of perfusion pressure may improve septic shock outcome.
Detailed Description
We will include severe infection patient who had evidence of organ dysfunction and hypotension and randomize into 2 groups as following: Control group. The patient will receive treatment according to septic shock guideline 2013, which start with intravenous fluid replacement until achieve target central venous pressure (CVP) or pulmonary capillary wedge pressure (PCWP) or other fluid responsive test goal. If the patient's mean arterial blood pressure still lower than 65 mmHg, then norepinephrine or dopamine will initiate to rise blood pressure. The patient will receive 5% dextrose water as the placebo of norepinephrine. Early norepinephrine group. The patient will receive fluid therapy together with low dose of norepinephrine (0.05 mcg/kg/min). If after titrate intravenous fluid therapy until achieve goal CVP or PCWP or other fluid responsive test, but the mean blood pressure still lower than 65 mmHg, then additional titrate dose of norepinephrine will be given to the patient according to standard septic shock guideline.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock, Severe Sepsis
Keywords
Septic shock, Severe sepsis, Norepinephrine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
310 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Early norepinephrine
Arm Type
Active Comparator
Arm Description
Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.
Intervention Type
Drug
Intervention Name(s)
Early norepinephrine
Other Intervention Name(s)
Early vasopressor therapy
Intervention Description
Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
5%D/W infusion as the placebo of norepinephrine.
Intervention Description
5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
Primary Outcome Measure Information:
Title
Therapeutic goal achievement
Description
Therapeutic goal including Mean arterial blood pressure > or = 65 mmHg Evidence of adequate tissue perfusion which include continuation of urine output > or = 0.5 ml/kg/hour for 2 hours or decreasing of serum lactate > or = 10 percent in 1 to 2 hours.
Time Frame
6 hours
Secondary Outcome Measure Information:
Title
Mortality rate
Time Frame
28 days
Other Pre-specified Outcome Measures:
Title
Survive with organ support free days
Description
The days that patient can survive without vasopressor, ventilator support and renal replacement therapy.
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > or = 18 years old Diagnosed severe sepsis or septic shock according to survival sepsis campaign 2013 Mean arterial pressure < 65 mmHg Exclusion Criteria: Pregnancy Severe underlying condition that unexpected to survive more than 48 hours Severe peripheral vascular disease Patient who required major surgery within 24 hours
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chairat Permpikul, MD
Organizational Affiliation
Mahidol University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Siriraj Hospital
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand

12. IPD Sharing Statement

Citations:
PubMed Identifier
23353941
Citation
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.
Results Reference
result
PubMed Identifier
30704260
Citation
Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. Am J Respir Crit Care Med. 2019 May 1;199(9):1097-1105. doi: 10.1164/rccm.201806-1034OC.
Results Reference
derived

Learn more about this trial

Early Use of Norepinephrine in Septic Shock Resuscitation

We'll reach out to this number within 24 hrs